#USA #New York #Securities Class Action #Faruqi & Faruqi #Picard Medical

PMI Deadline Alert: Key Information for Picard Medical Investors

On February 28, 2026, Faruqi & Faruqi, LLP, a prestigious national law firm specializing in securities law, issued a critical notice to investors of Picard Medical, Inc. (PMI). The firm is currently investigating possible claims against the company related to a federal securities class action, with an essential deadline of April 13, 2026. This article seeks to provide clarity on the allegations, deadlines, and options for affected investors.

Overview of the Allegations

The investigation by Faruqi & Faruqi centers around claims that Picard Medical and its executives may have breached federal securities laws. Key allegations from the complaint include that:
1. Picard was involved in a fraudulent stock promotion scheme that utilized social media misinformation and impersonation of financial professionals.
2. Insiders and affiliates reportedly engaged in share dumping through offshore accounts in a coordinated manner during a price inflation campaign.
3. Public statements from Picard failed to address material issues such as artificial trading activities and erroneous rumors that impacted stock prices significantly.

Market Reaction and Stock Performance

On October 24, 2025, shares of Picard Medical plummeted from $13.20 to $5.31 within a single trading session, marking a staggering drop of approximately 59.8%. This sudden decrease has garnered considerable attention and highlights the potential impact of the purported actions by the company's management.

Class Action and Leadership

In the class action scenario, the lead plaintiff is typically the investor who stands to gain the most in terms of recovery. This individual will guide the legal proceedings on behalf of other class members. Investors who incurred losses from September 2 to October 31, 2025, are encouraged to reach out to Faruqi & Faruqi for assistance on potentially becoming a lead plaintiff. Importantly, participation as a lead plaintiff does not affect the ability of other class members to claim recovery.

Next Steps for Investors

Faruqi & Faruqi is actively soliciting information related to Picard Medical's actions, especially from whistleblowers, former employees, and shareholders. The firm's partner, Josh Wilson, is available for direct contact at 877-247-4292 or 212-983-9330 (Ext. 1310) to discuss individual legal rights.

Conclusion

The upcoming April 13 deadline is crucial for investors looking to assert their rights in the ongoing federal securities class action against Picard Medical. As investigations proceed, affected stakeholders should stay informed and seek legal counsel to explore their options for making claims. More details on the class action can be found at Faruqi & Faruqi's official website.

Investors are advised to be proactive in addressing these developments to potentially secure favorable outcomes in the realm of securities laws.